NCT05308446 2026-04-13
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
32 trialsNCT06102902 2026-04-13
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05217446 2026-04-07
SEAMARK
Pfizer
Phase 2 Active not recruiting
NCT05039177 2026-03-25
HERKULES-3
Erasca, Inc.
Phase 1/2 Completed
NCT05985954 2026-03-12
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT07318389 2026-02-27
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Not yet recruiting
NCT05710406 2026-01-26
Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
Alliance for Clinical Trials in Oncology
Phase 2/3 Active not recruiting
NCT06578559 2026-01-05
BRICKET
Gruppo Oncologico del Nord-Ovest
Phase 2 Active not recruiting
NCT03803553 2025-12-23
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
Massachusetts General Hospital
Phase 3 Recruiting
NCT04017650 2025-11-20
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT05576896 2025-10-20
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
Northwestern University
Phase 2 Recruiting
NCT05510895 2025-10-01
NeoBRAF
AIO-Studien-gGmbH
Phase 2 Completed
NCT07178717 2025-09-17
REFISH
Vall d'Hebron Institute of Oncology
Phase 2 Not yet recruiting
NCT05706779 2025-09-02
NEORAF
Federation Francophone de Cancerologie Digestive
Phase 2 Recruiting
NCT04607421 2025-08-14
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Pfizer
Phase 3 Active not recruiting
NCT05743036 2025-08-08
ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1 Terminated
NCT05615818 2025-04-23
SAFIR-ABC10
UNICANCER
Phase 3 Recruiting
NCT05004350 2025-04-15
NAUTICALCRC
Pierre Fabre Medicament
Phase 2 Completed
NCT06640166 2025-02-12
ECLYPse
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2 Recruiting
NCT06411600 2024-11-08
BRAVE
Vall d'Hebron Institute of Oncology
Phase 2 Recruiting
NCT01436656 2024-10-28
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Pfizer
Phase 1 Completed
NCT04800822 2024-10-22
PF-07284892 in Participants With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT04390243 2024-05-06
Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation
Academic and Community Cancer Research United
Phase 2 Terminated
NCT03693170 2024-02-02
ANCHOR-CRC
Pierre Fabre Medicament
Phase 2 Completed
NCT02928224 2023-12-21
BEACON CRC
Pfizer
Phase 3 Completed
NCT05725200 2023-02-21
EVIDENT
Oslo University Hospital
Phase 2 Recruiting
NCT04044430 2023-01-09
Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer
University of California, San Francisco
Phase 1 Terminated
NCT02857270 2022-11-22
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
Eli Lilly and Company
Phase 1 Completed
NCT04673955 2022-09-29
BERING-CRC
Pierre Fabre Pharma GmbH
Recruiting
NCT02675946 2022-01-26
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Curegenix Inc.
Phase 1 Unknown
NCT01719380 2021-06-23
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
Pfizer
Phase 2 Completed
NCT02278133 2017-10-09
Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations
Array BioPharma
Phase 1/2 Completed